Second-line chemotherapy and its evaluation in small cell lung cancer
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date1999/08/01
-
Journal
-
Indian UGC (journal)
-
Refrences42
-
Citations42
-
C. Huisman
-
P.E. Postmus
-
G. Giaccone
-
E.F. Smit
Cite
Huisman, C., et al. “Second-Line Chemotherapy and Its Evaluation in Small Cell Lung Cancer”. Cancer Treatment Reviews, vol. 25, no. 4, 1999, pp. 199-06, https://doi.org/10.1053/ctrv.1999.0125.
Huisman, C., Postmus, P., Giaccone, G., & Smit, E. (1999). Second-line chemotherapy and its evaluation in small cell lung cancer. Cancer Treatment Reviews, 25(4), 199-206. https://doi.org/10.1053/ctrv.1999.0125
Huisman C, Postmus P, Giaccone G, Smit E. Second-line chemotherapy and its evaluation in small cell lung cancer. Cancer Treatment Reviews. 1999;25(4):199-206.
Journal Categories
Medicine
Internal medicine
Neoplasms
Tumors
Oncology
Including cancer and carcinogens
Medicine
Medicine (General)
You May Also Like
- Current and future therapeutic approaches for osteosarcoma
- HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
- Chemotherapy resistance in osteosarcoma: current challenges and future directions
- SPIKES—A Six-Step Protocol for Delivering Bad News: Application to the Patient with Cancer
- FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Topotecan versus cyclophosphamide, doxorubicin, and vincristine for treatment of recurrent small cell lung cancer | 1999 | |||
| Paclitaxel and carboplatin in the treatment of small cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide. A non-cross resistant schedule | 1999 | |||
| A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer | British Journal of Cancer |
| 116 | 1998 |
| Combination of Irinotecan and Etoposide for treatment of refractory or relapsed small cell lung cancer | 1998 | |||
| Small cell lung cancer, state-of-the-art therapy in 1996 | CHEST |
| 1997 |
Refrences Analysis
The category
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens 27
is the most frequently represented among the references in this article. It primarily includes studies from European Journal of Cancer The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Small cell lung cancer, current treatment and perspectives | Onkologie | 2023 | ||
| Platinum Re-Exposure as a Non-Small Cell Lung Cancer (NSCLC) Treatment Strategy in the Age of Immunotherapy | Clinical Lung Cancer |
| 2 | 2022 |
Real World Analysis of Small Cell Lung Cancer Patients: Prognostic Factors and Treatment Outcomes | Current Oncology |
| 12 | 2021 |
| Efficacy of Rechallenge of Metastatic Renal Cell Carcinoma Patient With Sunitinib After Prior Resistance to Axitinib: Case Report and Review of the Literature | Clinical Genitourinary Cancer |
| 1 | 2016 |
Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC | Molecular Cancer Therapeutics |
| 2016 |
Citations Analysis
The category
Medicine: Medicine (General) 37
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Clinical Perspectives on Platinum Resistance and was published in 2000. The most recent citation comes from a 2023 study titled Small cell lung cancer, current treatment and perspectives. This article reached its peak citation in 2001, with 5 citations. It has been cited in 29 different journals, 6% of which are open access. Among related journals, the Lung Cancer cited this research the most, with 7 citations. The chart below illustrates the annual citation trends for this article.